Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry
Open Access
- 20 June 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 10, 432
Abstract
Pharmacogenomics represents a potentially powerful enhancement to the current standard of care for psychiatric patients. However, a variety of biological and technical challenges must be addressed in order to provide adequate clinical decision support for personalized prescribing and dosing based on genomic data. This is particularly true in the case of CYP2D6, a key drug-metabolizing gene, which not only harbors multiple genetic variants known to affect enzyme function but also shows a broad range of copy-number and hybrid alleles in various patient populations. Here, we describe several challenges in the accurate measurement and interpretation of data from the CYP2D6 locus including the clinical consequences of increased copy number. We discuss best practices for overcoming these challenges and then explore various current and future applications of pharmacogenomic analysis of CYP2D6 in psychiatry.Keywords
This publication has 59 references indexed in Scilit:
- Sequencing the CYP2D6 Gene: From Variant Allele Discovery to Clinical Pharmacogenetic TestingPharmacogenomics, 2017
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicineGenomics, Proteomics & Bioinformatics, 2016
- Pharmacogenomics in the clinicNature, 2015
- Pharmacogenetics in Clinical Practice: How far Have we Come and where are we Going?Pharmacogenomics, 2013
- Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevanceClinical Proteomics, 2011
- Copy number variants in pharmacogenetic genesTrends in Molecular Medicine, 2011
- PharmacogenomicsCirculation, 2011
- CNVs of human genes and their implication in pharmacogeneticsCytogenetic and Genome Research, 2008
- Molecular Mechanism of Phase I and Phase II Drug‐Metabolizing Enzymes: Implications for Detoxification2007
- Inheritance and Drug ResponseNew England Journal of Medicine, 2003